OrbiMed Advisors LLC (“OrbiMed”), on behalf of its clients, has evaluated the Joint Proxy Statement/Prospectus for the proposed merger of Foamix Pharmaceuticals Ltd. (“Foamix”) and Menlo Therapeutics Inc. (“Menlo”).
Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (Foamix or the Company), a specialty pharmaceutical company, today announced the completion of Phase 2 clinical trial enrollment of FCD105 for the treatment of moderate-to-severe acne vulgaris. The trial will evaluate the efficacy and safety of the investigational topical combination foam, which comprises minocycline 3% and adapalene 0.3%.
Foamix Pharmaceuticals, based in Rehovot, Israel and Bridgewater, New Jersey, is merging with Menlo Therapeutics, based in Redwood City, California. The two companies will join to become a biopharma company focusing on dermatology.